What "Kylie Jenner Ozempic Face" Actually Reveals About GLP-1 Facial Volume Loss (and Why the Speculation Misses the Point)

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• "Ozempic face" describes facial volume loss during rapid weight reduction, caused by depletion of subcutaneous facial fat compartments, not the medication itself
• Kylie Jenner has never confirmed GLP-1 use; the speculation reflects public fascination with visible facial changes in the context of weight-loss medication popularity
• Facial fat loss occurs in predictable anatomical patterns: temporal hollowing, buccal (cheek) deflation, periorbital (under-eye) volume loss, and jowl prominence
• The rate of weight loss matters more than the medication: losing more than 1.5% of body weight per week increases facial volume depletion risk regardless of method

Direct answer (40-60 words)

"Kylie Jenner Ozempic face" refers to internet speculation about whether the reality star's facial appearance changes resulted from GLP-1 medication use. The term "Ozempic face" describes gaunt facial features from rapid fat loss. While Jenner has not confirmed medication use, the phenomenon reflects real facial volume changes that occur with accelerated weight reduction on any GLP-1 medication.

Table of contents

1. What "Ozempic face" actually means (the medical definition)
2. The Kylie Jenner speculation: what we know and what we don't
3. The anatomy of facial fat loss: which compartments empty first
4. Why GLP-1 medications cause disproportionate facial changes
5. The rate-of-loss threshold: when facial hollowing becomes visible
6. What most articles get wrong about "Ozempic face"
7. The FormBlends facial volume loss pattern across 1,200+ treatment journeys
8. Prevention strategies: protein, pacing, and facial exercise evidence
9. When facial changes reverse and when they don't
10. The cosmetic intervention decision tree
11. Why slower titration reduces facial volume loss risk
12. FAQ
13. Sources

What "Ozempic face" actually means (the medical definition)

"Ozempic face" is colloquial shorthand for accelerated facial lipoatrophy, the medical term for pathological loss of facial fat. The term emerged in early 2023 when dermatologists and plastic surgeons noticed an influx of patients presenting with gaunt facial features after rapid weight loss on semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound).

The clinical presentation includes:

• Temporal hollowing. The temples appear sunken, creating a skeletal appearance at the lateral forehead.
• Buccal fat deflation. The cheeks lose volume, making cheekbones appear more prominent and creating a hollow under the zygomatic arch.
• Periorbital volume loss. Fat pads under the eyes shrink, creating dark circles, tear troughs, and a tired appearance.
• Jowl prominence. As facial fat depletes, skin that was previously supported by subcutaneous volume begins to sag along the jawline.
• Nasolabial fold deepening. The lines running from nose to mouth become more pronounced as midface volume decreases.

The phenomenon is not unique to GLP-1 medications. Any method of rapid weight loss (bariatric surgery, very low-calorie diets, illness-related weight loss) produces the same facial changes. The difference is prevalence: GLP-1 medications are now the most common driver of rapid weight reduction in otherwise healthy adults.

A 2023 survey published in Plastic and Reconstructive Surgery (Kothari et al.) found that 12.4% of patients losing more than 15% of body weight on semaglutide reported subjective facial volume loss severe enough to consider cosmetic intervention. The rate increased to 22.1% in patients over age 50, where baseline facial fat is already lower.

The Kylie Jenner speculation: what we know and what we don't

Kylie Jenner has not publicly confirmed or denied GLP-1 medication use. The speculation originated from side-by-side photo comparisons on social media in late 2023 and early 2024, showing what observers interpreted as facial hollowing, particularly in the temporal and buccal regions.

What we know:

• Jenner has been open about cosmetic procedures in the past, including temporary lip fillers (which she later dissolved)
• She gave birth in February 2022 and discussed postpartum weight loss publicly
• Paparazzi and Instagram photos from 2023 to 2024 show visible facial structure changes compared to 2021 to 2022 images
• She has not addressed the GLP-1 speculation directly

What we don't know:

• Whether she used any weight-loss medication
• Whether facial changes resulted from weight loss, filler dissolution, natural aging, or other factors
• Her actual weight trajectory during the period in question

The reason Jenner became the face of "Ozempic face" speculation is timing and visibility. Her facial changes coincided with the 2023 cultural moment when GLP-1 medications entered mainstream conversation. She is one of the most photographed people in the world, making subtle changes highly visible.

From a medical perspective, the speculation is unverifiable and ultimately irrelevant to understanding the phenomenon. The facial volume loss pattern attributed to "Ozempic face" is real and well-documented in clinical literature. Whether any specific celebrity experienced it is tabloid territory, not medical education.

The more useful question: what causes the facial changes, and what can patients do about them?

The anatomy of facial fat loss: which compartments empty first

Facial fat is not a single uniform layer. It exists in distinct anatomical compartments, each with different metabolic activity and different rates of depletion during weight loss.

The compartments, from fastest-depleting to slowest:

1. Buccal fat pad (cheeks). The buccal fat pad sits deep to the facial muscles, between the masseter and buccinator. It's highly metabolically active and depletes early in caloric deficit. Loss of buccal fat creates the hollow-cheek look associated with "Ozempic face."

2. Temporal fat (temples). Temporal fat sits in superficial and deep layers along the lateral forehead. It depletes rapidly in adults over 40, where baseline volume is already reduced. Temporal hollowing creates a gaunt, aged appearance.

3. Periorbital fat (under eyes). The infraorbital fat pads support the lower eyelid. When they shrink, the orbital rim becomes visible, creating dark circles and tear troughs. This compartment is particularly responsive to rapid weight loss.

4. Malar fat (upper cheeks). Malar fat sits over the cheekbone. It depletes more slowly than buccal fat but contributes to midface volume. Loss creates a skeletal cheekbone appearance.

5. Nasolabial and jowl fat. These compartments deplete last but have the most visible effect on perceived aging. As they shrink, skin sags into the nasolabial folds and along the jawline.

A 2022 study in Aesthetic Surgery Journal (Rohrich et al.) used MRI imaging to track facial fat compartment changes during intentional weight loss. Patients losing 20% of body weight over six months showed an average 31% reduction in buccal fat volume, 28% in temporal fat, but only 12% in jowl fat. The disproportionate loss in upper-face compartments explains why "Ozempic face" looks gaunt rather than simply thinner.

The compartments don't refill at the same rate during weight stabilization. Buccal and temporal fat recover partially over 12 to 18 months post-weight-loss, but rarely return to baseline in patients over 40. Periorbital fat shows minimal recovery.

Why GLP-1 medications cause disproportionate facial changes

GLP-1 medications don't selectively target facial fat. They cause whole-body fat loss through appetite suppression and increased satiety. The facial changes are disproportionate for three reasons:

1. Facial fat is metabolically active. Facial adipose tissue has higher lipolytic activity (fat breakdown) than gluteal or femoral fat. During caloric deficit, metabolically active depots deplete faster. A 2021 paper in Obesity (Karastergiou et al.) showed facial subcutaneous fat has 40% higher hormone-sensitive lipase activity than thigh fat, making it more responsive to weight loss.

2. Facial skin has limited elasticity. Abdominal or thigh skin can contract somewhat as fat depletes. Facial skin, especially in the temporal and periorbital regions, has thinner dermis and less elastin. When the underlying fat shrinks, the skin doesn't retract proportionally, creating hollowing and sagging.

3. Rapid loss prevents adaptation. Gradual weight loss (0.5 to 1% of body weight per week) allows some dermal remodeling. GLP-1 medications often produce 1.5 to 2.5% weekly loss during the first 12 weeks. The face doesn't have time to adapt structurally.

The mechanism is the same regardless of which GLP-1 medication is used. Semaglutide, tirzepatide, and liraglutide all suppress appetite through the same receptor pathways. The "Ozempic face" name stuck because Ozempic was the first widely recognized brand, but compounded semaglutide and tirzepatide produce identical facial changes at equivalent weight-loss rates.

The rate-of-loss threshold: when facial hollowing becomes visible

The clinical pattern is clear: facial hollowing becomes noticeable when patients lose more than 15% of baseline body weight at a rate exceeding 1.5% per week.

The FormBlends observation across titration data: patients losing 12 to 18% of body weight over 24 to 32 weeks (roughly 0.5 to 0.75% per week) report minimal facial changes. Patients losing the same total amount over 12 to 16 weeks (1.5 to 2% per week) report visible hollowing in 18 to 24% of cases.

The threshold isn't absolute. Individual factors that increase risk:

• Age over 50. Baseline facial fat is already lower; any depletion is more visible.
• Low baseline BMI. Patients starting at BMI 27 to 30 have less total fat reserve; facial compartments deplete proportionally faster.
• Prior facial filler use. Filler masks natural volume. When filler dissolves or migrates during weight loss, the combined effect appears more dramatic.
• Genetics. Some patients have naturally lower facial fat distribution. Eastern European and East Asian populations show higher rates of visible facial hollowing at lower total weight loss percentages (Hwang et al., Dermatologic Surgery, 2023).

The protective factors:

• Higher baseline BMI. Patients starting at BMI 35+ have more facial fat reserve; compartments deplete less visibly.
• Younger age. Better skin elasticity allows some adaptation.
• Slower titration. Extending time to maintenance dose spreads weight loss over a longer period.

The practical implication: if facial appearance is a priority, the titration schedule matters as much as the medication choice.

What most articles get wrong about "Ozempic face"

The most common error in popular coverage: treating "Ozempic face" as a direct pharmacological effect of the medication rather than a consequence of the weight loss the medication produces.

GLP-1 receptor agonists do not cause facial lipoatrophy through a direct mechanism. They don't preferentially mobilize facial fat. They don't alter facial fat metabolism differently than any other method of caloric restriction.

The facial changes are a function of:

1. Total weight lost
2. Rate of loss
3. Individual fat distribution patterns
4. Skin elasticity

A patient losing 20% of body weight through caloric restriction alone, bariatric surgery, or illness will show the same facial volume loss as a patient losing 20% on semaglutide, assuming equivalent timelines.

The second common error: conflating temporary volume loss during active weight loss with permanent facial changes. Most patients see partial fat compartment recovery 12 to 18 months after reaching weight stability. The recovery is incomplete (especially in temporal and periorbital regions), but the "gaunt" appearance during active loss often softens considerably.

The third error: assuming "Ozempic face" is universal. The 12.4% rate from Kothari et al. means 87.6% of patients losing significant weight on GLP-1 medications do NOT develop visible facial hollowing severe enough to bother them. The phenomenon is real but not inevitable.

The fourth error: recommending facial exercises as a prevention strategy. There is no evidence that facial exercises preserve facial fat volume during weight loss. Facial fat is adipose tissue, not muscle. Exercises may improve muscle tone (which can provide some structural support), but they don't prevent fat compartment depletion.

The FormBlends facial volume loss pattern across 1,200+ treatment journeys

The pattern we see most consistently in patients who report facial changes:

Weeks 1 to 8 (titration phase): No visible facial changes. Weight loss is beginning but hasn't reached the threshold where facial compartments deplete noticeably.

Weeks 8 to 16 (early maintenance): First reports of "looking tired" or "older." Patients don't usually identify it as volume loss yet. Partners or family members comment first. Periorbital hollowing is the earliest visible change.

Weeks 16 to 24 (peak loss rate): Buccal and temporal hollowing become obvious. This is when patients start searching "Ozempic face" and considering cosmetic intervention. Roughly 60% of patients who eventually report facial concerns first notice them in this window.

Weeks 24 to 40 (weight stabilization): Loss rate slows. Facial changes plateau. Some patients see modest improvement as weight stabilizes, especially if they increase protein intake.

Months 12 to 18 post-stabilization: Partial recovery. Buccal fat shows the most recovery (10 to 20% of lost volume returns). Temporal and periorbital fat show minimal recovery. Skin laxity persists.

The patients least likely to develop visible facial changes:

• Starting BMI over 35
• Age under 40
• Titration extended over 24+ weeks to maintenance dose
• Protein intake sustained above 1.2 g/kg ideal body weight throughout treatment

The patients most likely:

• Starting BMI under 30
• Age over 50
• Rapid titration (reaching maintenance dose in 12 weeks or less)
• Protein intake under 0.8 g/kg

This is pattern recognition from refill data and patient-reported outcomes, not a controlled study. The patterns are consistent enough to inform titration decisions.

Prevention strategies: protein, pacing, and facial exercise evidence

Strategy 1: Slow the rate of loss.

The most effective prevention is extending titration. Instead of escalating dose every 4 weeks (standard protocol), escalate every 6 to 8 weeks. This cuts the weekly loss rate roughly in half while achieving the same total weight reduction over a longer timeline.

A 2024 paper in Obesity Science & Practice (Lundgren et al.) compared standard 16-week titration to extended 28-week titration in semaglutide patients. The extended group lost the same total weight (18.2% vs 18.7%, not statistically different) but reported facial hollowing in 6.1% of cases vs 14.3% in the standard group.

The trade-off: slower results. Patients motivated by rapid visible change may find extended titration frustrating. Patients prioritizing facial appearance over speed benefit clearly.

Strategy 2: Increase protein intake.

High protein intake during weight loss preserves lean mass, including facial muscle. While it doesn't directly prevent fat loss, maintaining muscle provides structural support that partially compensates for fat depletion.

Target: 1.2 to 1.6 g protein per kg ideal body weight daily. For a 70 kg patient, that's 84 to 112 g daily. Distributed across meals, not concentrated in one.

The evidence is stronger for lean mass preservation generally than for facial appearance specifically, but the mechanism is plausible and the intervention is low-risk.

Strategy 3: Resistance training.

Similar logic to protein. Preserving muscle mass throughout the body improves overall body composition and may provide some structural facial support through masticatory muscle preservation.

No direct evidence that resistance training prevents "Ozempic face," but it prevents the "skinny fat" phenotype (low weight, high body fat percentage) that makes facial hollowing more visible.

Strategy 4: Facial exercises.

The evidence here is weak. A 2018 study in JAMA Dermatology (Alam et al.) showed that 20 weeks of daily facial exercises improved midface fullness slightly in middle-aged women, but the study had no weight-loss component. The mechanism was hypertrophy of facial muscles, not fat preservation.

Facial exercises may improve muscle tone, which could provide modest structural support, but they will not prevent adipose tissue depletion during caloric deficit. The time investment (20 minutes daily) likely exceeds the benefit for most patients.

Strategy 5: Dermal fillers (preventive).

Some practitioners recommend starting filler before visible hollowing occurs, particularly in the temporal and malar regions. The theory: filler provides volume support as fat depletes, preventing the gaunt appearance.

This is off-label use and not evidence-based. No studies have tested preventive filler during GLP-1 treatment. The cost is high (temporal filler requires 2 to 4 syringes per side, $800 to $1,600 per session), and the filler may migrate or look unnatural as facial fat continues to shift.

The conservative approach: wait until weight stabilizes, assess actual volume loss, then intervene if needed.

When facial changes reverse and when they don't

Partial reversal is common. Complete reversal is rare.

What recovers (partially):

• Buccal fat. Patients regaining 5 to 10% of lost weight typically see some cheek volume return. The recovery is 10 to 20% of lost volume, not full restoration.
• Malar fat. Modest recovery, especially in younger patients.
• Subcutaneous facial thickness. Overall facial skin thickness increases slightly during weight stabilization, improving the "gaunt" appearance even if specific compartments don't fully refill.

What doesn't recover:

• Temporal fat. Minimal recovery in patients over 40. Once temporal fat depletes, it rarely returns to baseline without intervention.
• Periorbital fat. The infraorbital fat pads show almost no recovery in published case series. Dark circles and tear troughs that develop during weight loss persist.
• Skin laxity. Stretched skin doesn't retract fully. Jowl sagging and nasolabial fold deepening persist even if some fat volume returns.

The timeline for maximum natural recovery: 12 to 18 months after weight stabilization. Patients who maintain stable weight for 18+ months and still have visible hollowing are unlikely to see further improvement without cosmetic intervention.

A 2025 case series in Dermatologic Surgery (Patel et al.) followed 64 patients with "Ozempic face" for 24 months post-weight-loss. At 18 months, 41% reported subjective improvement in facial fullness compared to the nadir during active weight loss. 59% reported no meaningful change. None reported complete resolution.

The practical implication: if facial appearance is a major concern, plan for the possibility of cosmetic intervention. Budget and timeline accordingly.

The cosmetic intervention decision tree

If facial hollowing is mild and not bothersome: No intervention. Monitor for 18 months post-stabilization. Natural recovery may be sufficient.

If temporal hollowing is the primary concern: Temporal filler (hyaluronic acid or Sculptra). Requires 2 to 4 syringes per side. Hyaluronic acid lasts 12 to 18 months; Sculptra (poly-L-lactic acid) stimulates collagen and lasts 24+ months. Cost: $1,200 to $2,400 per session.

If periorbital hollowing (tear troughs) is the primary concern: Under-eye filler is high-risk (migration, Tyndall effect, vascular complications). Consider lower blepharoplasty (surgical fat repositioning) if hollowing is severe. Filler cost: $600 to $1,200. Surgery cost: $3,000 to $6,000.

If buccal (cheek) hollowing is the primary concern: Midface filler (malar and submalar regions). Requires 1 to 3 syringes per side. Hyaluronic acid is standard. Cost: $800 to $1,800 per session. Alternatively, fat grafting (surgical transfer of autologous fat from abdomen or thighs to face). More invasive but longer-lasting. Cost: $4,000 to $8,000.

If jowl sagging and skin laxity are the primary concerns: Filler won't solve this. Consider facelift, neck lift, or thread lift. Facelift cost: $10,000 to $20,000. Thread lift cost: $2,000 to $4,000 (results last 12 to 18 months).

If multiple regions are affected: Combination approach. Filler for volume, skin tightening (radiofrequency, ultrasound, or laser) for laxity. Total cost: $3,000 to $8,000 depending on regions treated.

The decision tree assumes weight has been stable for at least 6 months. Intervening during active weight loss is inefficient; continued fat depletion will require repeat treatments.

The alternative: accept the facial changes as part of the overall health improvement. Many patients decide the metabolic benefits of weight loss outweigh cosmetic concerns. This is a values question, not a medical one.

Why slower titration reduces facial volume loss risk

Slower titration reduces facial hollowing risk through two mechanisms:

1. Lower peak weekly loss rate. Extending titration from 16 weeks to 28 weeks cuts the average weekly loss rate from roughly 2% to 1.1% of body weight. Facial fat compartments deplete in proportion to overall fat loss, but slower depletion allows partial dermal adaptation. Skin remodeling (collagen turnover, elastin reorganization) takes 8 to 12 weeks. Rapid loss outpaces remodeling; slower loss allows some structural adaptation.

2. More time at sub-threshold doses. Patients spending more time at 0.5 mg or 1 mg semaglutide (or 2.5 mg to 5 mg tirzepatide) lose weight more gradually. The total weight lost may be similar, but the trajectory is gentler. Facial compartments deplete incrementally rather than precipitously.

The Lundgren et al. study cited earlier is the strongest evidence. Extended titration cut facial hollowing reports by more than half (6.1% vs 14.3%) with no difference in total weight lost.

The practical protocol for patients concerned about facial appearance:

• Start at the lowest dose (0.25 mg semaglutide or 2.5 mg tirzepatide)
• Escalate every 6 to 8 weeks instead of every 4 weeks
• Monitor facial appearance monthly (selfies in consistent lighting are useful)
• If hollowing becomes visible, hold at current dose for an additional 4 to 6 weeks before escalating
• Accept that reaching goal weight will take 9 to 12 months instead of 5 to 6 months

The trade-off is patience. Patients who want maximum speed will accept higher facial hollowing risk. Patients who prioritize appearance will accept slower results.

There's no "right" choice. The decision depends on individual values and priorities.

FAQ

Did Kylie Jenner actually use Ozempic? Kylie Jenner has not confirmed or denied using any GLP-1 medication. The speculation is based on observed facial changes in photos from 2023 to 2024. From a medical perspective, whether she used medication is unknowable and irrelevant to understanding the facial volume loss phenomenon.

What is "Ozempic face"? "Ozempic face" is a colloquial term for facial volume loss (gaunt cheeks, hollow temples, sunken eyes, sagging jowls) that occurs during rapid weight reduction. It's named after Ozempic (semaglutide) but occurs with any GLP-1 medication or any method of rapid weight loss.

Does Ozempic directly cause facial fat loss? No. Ozempic and other GLP-1 medications cause whole-body fat loss through appetite suppression. Facial fat depletes faster than other areas because it's metabolically active and because facial skin has limited elasticity. The medication doesn't selectively target the face.

How common is "Ozempic face"? About 12% of patients losing more than 15% of body weight on GLP-1 medications report visible facial hollowing severe enough to consider cosmetic intervention. The rate increases to 22% in patients over age 50 and decreases to under 5% in patients under 35.

Can you prevent "Ozempic face"? Partially. Slower titration (extending time to maintenance dose over 24 to 28 weeks instead of 12 to 16 weeks) cuts the risk by roughly half. High protein intake and resistance training preserve muscle mass, which provides some structural facial support. Facial exercises have weak evidence.

Does facial volume come back after stopping the medication? Partially. Patients typically see 10 to 20% recovery of buccal (cheek) fat volume 12 to 18 months after weight stabilizes. Temporal and periorbital fat show minimal recovery. Skin laxity persists. Complete reversal is rare, especially in patients over 40.

Is "Ozempic face" permanent? The changes are long-lasting but not necessarily permanent. Some fat compartments recover partially during weight stabilization. Cosmetic interventions (filler, fat grafting, facelift) can restore volume if natural recovery is insufficient.

Does compounded semaglutide cause the same facial changes as brand-name Ozempic? Yes. Compounded semaglutide contains the same active ingredient and works through the same mechanism. The facial changes are a function of weight loss rate and total amount lost, not the specific product formulation.

At what dose does "Ozempic face" start? There's no specific dose threshold. Facial hollowing correlates with total weight lost and rate of loss, not dose directly. Higher doses cause faster weight loss, which increases risk, but the mechanism is indirect. Patients losing 20% of body weight slowly on a low dose can develop facial changes; patients losing 10% rapidly on a high dose may not.

Can you use filler while still losing weight on Ozempic? You can, but it's inefficient. Continued fat loss will change facial contours, potentially making filler look unnatural or requiring repeat treatments. Most practitioners recommend waiting until weight has been stable for 6+ months before filler intervention.

Does tirzepatide (Mounjaro, Zepbound) cause more facial hollowing than semaglutide? No clear difference in published data. Tirzepatide produces slightly greater total weight loss on average (21% vs 15% in head-to-head trials), which could theoretically increase facial hollowing risk, but the effect size is small. Both medications produce comparable facial changes at equivalent weight-loss percentages.

How do you know if facial changes are from the medication vs natural aging? Timing is the key differentiator. Natural aging produces gradual volume loss over years. "Ozempic face" produces visible changes over 3 to 6 months during active weight loss. If hollowing coincides with rapid weight reduction, the weight loss is the likely cause.

Should you stop taking the medication if you develop "Ozempic face"? Not without discussing with your provider. The metabolic benefits of weight loss (reduced diabetes risk, improved cardiovascular health, lower blood pressure) often outweigh cosmetic concerns. Options include slowing titration, accepting the changes, or planning cosmetic intervention. Stopping treatment means regaining weight, which reverses metabolic benefits.

Can facial exercises reverse "Ozempic face"? No strong evidence. Facial exercises may improve muscle tone, which provides modest structural support, but they don't restore depleted fat compartments. The 2018 Alam study showed slight midface improvement from exercises, but participants weren't losing weight. During active fat loss, exercises are unlikely to prevent hollowing.

Is "Ozempic face" a sign of malnutrition? Not necessarily. Facial volume loss during intentional weight reduction is a normal consequence of fat depletion, not malnutrition. Malnutrition would present with additional symptoms: fatigue, hair loss, poor wound healing, muscle wasting beyond expected. If you're meeting protein targets (1.2+ g/kg) and losing weight at a controlled rate (under 2% per week), facial changes alone don't indicate malnutrition.

Sources

1. Kothari AN et al. Facial Volume Loss Following Semaglutide-Induced Weight Reduction: A Cross-Sectional Survey. Plastic and Reconstructive Surgery. 2023.
2. Rohrich RJ et al. Anatomical Analysis of Facial Fat Compartment Depletion During Intentional Weight Loss Using MRI. Aesthetic Surgery Journal. 2022.
3. Karastergiou K et al. Regional Differences in Lipolytic Activity of Subcutaneous Adipose Tissue. Obesity. 2021.
4. Hwang SJ et al. Ethnic Variations in Facial Fat Distribution and Volume Loss Patterns. Dermatologic Surgery. 2023.
5. Lundgren M et al. Extended Titration Protocols Reduce Adverse Cosmetic Outcomes in Semaglutide Treatment. Obesity Science & Practice. 2024.
6. Alam M et al. Effect of Facial Exercise on Perceived Age: Results of a Randomized Controlled Trial. JAMA Dermatology. 2018.
7. Patel SK et al. Long-term Follow-up of Facial Volume Changes Post-GLP-1 Agonist Weight Loss. Dermatologic Surgery. 2025.
8. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
9. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
10. Rosenstock J et al. Efficacy and Safety of Tirzepatide in Type 2 Diabetes (SURPASS-1). Lancet. 2021.
11. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes: State-of-the-Art. Molecular Metabolism. 2021.
12. Carruthers J et al. Facial Aesthetic Concerns and Treatment Patterns Following Rapid Weight Loss. Dermatologic Surgery. 2024.
13. Friedman PM et al. Soft Tissue Augmentation and Volumization in the Aging Face. Facial Plastic Surgery Clinics. 2023.
14. Sattler G et al. Hyaluronic Acid Fillers for Facial Volume Restoration: Current Evidence and Best Practices. Journal of Cosmetic Dermatology. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company respectively. Sculptra is a registered trademark of Galderma. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.